drugset
drugset / Trial / NCT04942964

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT04942964 ↗

Phase 1 Completed 25 enrolled Astellas Pharma Global Development, Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the effect of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function. The study will also evaluate the safety and tolerability of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function.

Timeline

Start
2021-09-13
Primary completion
2022-01-11
Completion
2022-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Bocidelpar Small molecule — Oral

Indications

No indication recorded.